18 papers
By reusing discarded plasma samples from a hospital biobank linked to electronic medical records, this pilot study demonstrated that concomitant use of CYP3A4 and P-gp inhibitors significantly increases apixaban plasma concentrations in patients, supporting the hypothesis that elevated drug levels mediate increased bleeding risk.
This systematic review and meta-analysis of randomized controlled trials concludes that there is no evidence supporting the efficacy of higher-dose fluvoxamine in preventing disease deterioration or hospitalization in adults with mild-to-moderate COVID-19, citing significant heterogeneity and bias across the included studies.
This Phase 2 trial demonstrates that TTI-0102, a novel controlled-release cysteamine prodrug, is safe and well-tolerated in MELAS patients at weight-based doses of 60 mg/kg, showing significant improvements in fatigue and favorable modulation of mitochondrial biomarkers, thereby supporting its advancement to larger trials for mitochondrial diseases and cystinosis.
This Phase 1, randomized, double-blind, placebo-controlled study demonstrated that intravenous recombinant human plasma gelsolin (rhu-pGSN) is safe, well-tolerated, and exhibits a half-life supporting once-daily dosing in healthy volunteers at doses up to 24 mg/kg.
This study of 355 healthcare workers at a tertiary care hospital in Uttarakhand, India, reveals moderate adherence (52.3%) to CDC antimicrobial stewardship core elements, which is significantly hindered by systemic barriers such as drug shortages, personnel deficits, delayed lab reports, and insufficient training.
This study provides the first human proof-of-concept that a 12-week course of the FDA-approved antiretroviral regimen FTC/TAF, but not FTC/TDF, significantly reduces biological age and inflammatory biomarkers in healthy adults, supporting the potential of retrotransposon-targeted gerotherapeutics.
The paper introduces COMPASS, a pan-cancer foundation model that leverages a concept-bottleneck transformer to accurately predict immunotherapy response across diverse cancers and treatments by encoding gene expression into 44 biologically grounded immune concepts, thereby outperforming existing baselines while providing interpretable mechanistic insights into resistance.
The paper introduces REACT, a scalable framework that automates target trial emulation using real-world data to systematically screen drugs for repurposing, successfully identifying 18 candidates with significant associations to osteoporotic fracture prevention.
The Medicines in Acute and Chronic Care in Scotland (MACCS) resource is a curated, national-level dataset that integrates and harmonizes diverse prescribing and clinical records from multiple healthcare settings to enable robust, longitudinal research on medicine exposure and health outcomes within the NHS Scotland system.
This cohort study identifies a novel drug-drug interaction where concomitant use of dihydropyridine calcium channel blockers significantly amplifies the risk of dementia, particularly unspecified types, in patients initiating gabapentin therapy, suggesting a reversible, drug-induced cognitive impairment mechanism.
This study demonstrates that while Mendelian randomization (MR) statistical significance alone fails to predict clinical trial success, integrating diverse MR-derived features into machine learning models significantly enriches the prioritization of drug targets, achieving a 55% approval rate and outperforming both unstratified programs and GWAS-supported targets.
This pilot trial demonstrates that a multi-modal, multi-organ imaging battery is feasible for assessing geroprotective interventions like rapamycin in humans, showing high completion rates for most modalities and revealing exploratory improvements in cardiac, retinal, and metabolic parameters over a 26-week period in patients with early Alzheimer's disease.
This study reveals that pain frequency acts as a critical contextual factor that differentially shapes the relationship between cannabis use metrics (such as cumulative duration versus daily dosage) and functional connectivity within the brain's default mode network.
This study reveals that mass-compounded tirzepatide/B12 products widely marketed in the U.S. contain a novel, previously unidentified impurity formed by a chemical reaction between the drug and vitamin B12 analogs, raising significant patient safety concerns due to the lack of FDA evaluation for these untested combinations.
This study analyzes Tanzania's 2010–2016 antibiotic import data to reveal that pricing is systematically influenced by formulation type, supplier origin, and naming practices, highlighting the need for import-level monitoring to guide procurement and stewardship policies in low- and middle-income countries.
This proof-of-concept study demonstrates that a hybrid AI-driven clinical decision support system for vancomycin therapeutic monitoring is technically feasible and accurate in foundational calculations, but requires mandatory expert oversight and deterministic safeguards to address limitations in predictive reasoning, timing recommendations, and safety enforcement before clinical implementation.
This study developed and validated a population pharmacokinetic model for a novel intravenous topiramate formulation in epilepsy and migraine patients, identifying enzyme-inducing co-medications as a key factor increasing clearance and demonstrating that dose adjustments can effectively maintain therapeutic plasma concentrations.
This study evaluated the performance of biomedical Large Language Models combined with specific prompting strategies and causality algorithms on 150 Individual Case Safety Reports, finding that while the Medicine LLaMA-3 8B model with Chain-of-Thought prompting achieved the highest agreement with human experts (64%), these models remain suboptimal for reliable individual-level causality assessment in pharmacovigilance.